Zimmer Biomet’s (ZBH) Hold Rating Reiterated at Needham & Company LLC

Zimmer Biomet (NYSE:ZBH)‘s stock had its “hold” rating reaffirmed by analysts at Needham & Company LLC in a report released on Tuesday,Benzinga reports.

ZBH has been the topic of several other reports. JPMorgan Chase & Co. reiterated a “neutral” rating and set a $100.00 price target (down from $115.00) on shares of Zimmer Biomet in a research report on Thursday, November 6th. Johnson Rice set a $112.00 price objective on Zimmer Biomet in a report on Wednesday, November 5th. Evercore upgraded Zimmer Biomet from an “in-line” rating to an “outperform” rating and raised their target price for the company from $94.00 to $120.00 in a report on Monday, January 5th. Barclays cut their target price on shares of Zimmer Biomet from $112.00 to $105.00 and set an “underweight” rating for the company in a research report on Wednesday, November 5th. Finally, Robert W. Baird restated a “neutral” rating and set a $100.00 price objective (down previously from $117.00) on shares of Zimmer Biomet in a report on Tuesday, December 16th. One research analyst has rated the stock with a Strong Buy rating, eight have assigned a Buy rating, nine have given a Hold rating and three have issued a Sell rating to the company. Based on data from MarketBeat, the company currently has a consensus rating of “Hold” and an average price target of $106.10.

Zimmer Biomet Stock Up 2.8%

NYSE ZBH traded up $2.55 on Tuesday, reaching $92.28. The company had a trading volume of 1,834,863 shares, compared to its average volume of 2,279,722. Zimmer Biomet has a 1 year low of $84.59 and a 1 year high of $114.44. The company has a debt-to-equity ratio of 0.59, a current ratio of 2.43 and a quick ratio of 1.39. The firm has a market capitalization of $18.29 billion, a PE ratio of 22.86, a P/E/G ratio of 2.29 and a beta of 0.62. The firm has a 50-day moving average of $90.02 and a 200-day moving average of $95.68.

Zimmer Biomet (NYSE:ZBH) last announced its quarterly earnings data on Tuesday, February 10th. The medical equipment provider reported $2.42 earnings per share for the quarter, topping the consensus estimate of $2.38 by $0.04. The company had revenue of $2.24 billion during the quarter, compared to analyst estimates of $2.22 billion. Zimmer Biomet had a net margin of 10.05% and a return on equity of 12.85%. The firm’s revenue for the quarter was up 10.9% compared to the same quarter last year. During the same period last year, the business earned $2.31 EPS. Zimmer Biomet has set its FY 2026 guidance at 8.300-8.450 EPS. On average, equities research analysts anticipate that Zimmer Biomet will post 8.22 EPS for the current fiscal year.

Institutional Investors Weigh In On Zimmer Biomet

Hedge funds have recently bought and sold shares of the company. Brighton Jones LLC bought a new stake in Zimmer Biomet during the fourth quarter worth $204,000. Sivia Capital Partners LLC bought a new stake in shares of Zimmer Biomet during the second quarter worth about $232,000. IFP Advisors Inc lifted its holdings in shares of Zimmer Biomet by 8.3% during the second quarter. IFP Advisors Inc now owns 1,947 shares of the medical equipment provider’s stock worth $178,000 after purchasing an additional 149 shares during the period. Aberdeen Group plc boosted its holdings in Zimmer Biomet by 9.9% in the second quarter. Aberdeen Group plc now owns 172,438 shares of the medical equipment provider’s stock valued at $15,728,000 after acquiring an additional 15,536 shares during the last quarter. Finally, OFI Invest Asset Management bought a new position in shares of Zimmer Biomet in the 2nd quarter worth about $83,000. 88.89% of the stock is currently owned by institutional investors and hedge funds.

Key Zimmer Biomet News

Here are the key news stories impacting Zimmer Biomet this week:

• Positive Sentiment: Q4 beat on both EPS and revenue: reported $2.42 EPS vs. $2.38 consensus and revenue of $2.24B (sales +10.9% year-over-year), reflecting continued demand for orthopedics. Zimmer Biomet beats quarterly estimates on strong hips, knees device demand
• Neutral Sentiment: Revenue and EPS growth were solid vs. prior year, but investors should dig into product/region breakdowns and conference call commentary for sustainability. Zimmer Biomet (ZBH) Q4 Earnings and Revenues Top Estimates
• Neutral Sentiment: Analyst consensus remains muted—street rating recently shown as a “Hold”—so upgrades/downgrades will matter more than the beat itself for further moves. Zimmer Biomet Holdings, Inc. (NYSE:ZBH) Given Consensus Rating of “Hold” by Analysts
• Negative Sentiment: FY2026 guidance was conservative relative to consensus: EPS guidance of $8.30–8.45 (consensus ~8.44) and revenue guidance roughly $8.4B–$8.6B (consensus ~8.6B), which may cap upside if investors expected a clearer beat. ZBH Q4 Earnings & Revenues Top Estimates, Stock Up in Pre-Market
• Negative Sentiment: Management noted margin contraction in the quarter, which pressures near-term profitability metrics and could weigh on multiple expansion until margin trends reverse. ZBH Q4 Earnings & Revenues Top Estimates, Stock Up in Pre-Market

Zimmer Biomet Company Profile

Zimmer Biomet (NYSE: ZBH) is a global medical device company focused on musculoskeletal healthcare. Headquartered in Warsaw, Indiana, the company designs, manufactures and markets a broad portfolio of products used to treat joint disorders, bone disorders and related conditions. Its customer base includes orthopaedic and dental surgeons, hospitals, ambulatory surgery centers and other healthcare providers that rely on implants, instruments and related services for reconstructive and restorative procedures.

The company’s product offerings span joint replacement systems for hips, knees and shoulders; trauma and extremities implants; spine and thoracic solutions; dental and craniomaxillofacial implants and prosthetics; and sports medicine devices.